Hosking Partners LLP raised its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 87,858 shares of the medical research company’s stock after acquiring an additional 371 shares during the period. Hosking Partners LLP owned approximately 0.30% of Bio-Rad Laboratories worth $19,524,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Canada Pension Plan Investment Board acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at $113,000. Pacad Investment Ltd. acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at $113,000. First Manhattan Co. lifted its stake in shares of Bio-Rad Laboratories by 71.6% in the 3rd quarter. First Manhattan Co. now owns 599 shares of the medical research company’s stock valued at $133,000 after purchasing an additional 250 shares during the period. Turner Investments LLC acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at $136,000. Finally, Meeder Asset Management Inc. lifted its stake in shares of Bio-Rad Laboratories by 3,333.3% in the 3rd quarter. Meeder Asset Management Inc. now owns 618 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 600 shares during the period. Institutional investors and hedge funds own 62.76% of the company’s stock.
Several research firms recently issued reports on BIO. TheStreet cut shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research note on Thursday, August 3rd. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research note on Tuesday, November 7th. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a $255.00 target price on shares of Bio-Rad Laboratories in a research note on Monday, September 18th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $260.00.
Shares of Bio-Rad Laboratories, Inc. (BIO) opened at $262.14 on Monday. The company has a market cap of $7,802.07, a price-to-earnings ratio of 83.22, a P/E/G ratio of 3.96 and a beta of 0.88. The company has a quick ratio of 2.77, a current ratio of 4.06 and a debt-to-equity ratio of 0.15. Bio-Rad Laboratories, Inc. has a 1-year low of $170.81 and a 1-year high of $268.40.
Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.54 by $0.37. The company had revenue of $535.00 million during the quarter, compared to analyst estimates of $507.99 million. Bio-Rad Laboratories had a net margin of 1.15% and a return on equity of 3.44%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.62 EPS. analysts expect that Bio-Rad Laboratories, Inc. will post 2.65 earnings per share for the current year.
In related news, EVP Giovanni Magni sold 2,400 shares of the business’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $253.01, for a total value of $607,224.00. Following the completion of the sale, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $2,340,595.51. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 28.29% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: “Hosking Partners LLP Increases Holdings in Bio-Rad Laboratories, Inc. (BIO)” was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://transcriptdaily.com/2017/11/27/hosking-partners-llp-increases-holdings-in-bio-rad-laboratories-inc-bio.html.
Bio-Rad Laboratories Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.